(CercleFinance.com) – Abionyx Pharma announces that it has carried out a capital increase of around three million euros (bonus included) for the benefit of categories of people, intended to strengthen the cash flow of the biotechnology company.
This operation resulted in the full subscription of 2,967,352 new shares at a price of 1.011 euros per share, representing approximately 10.21% of the number of shares in circulation before issuance and 9.27% after issuance.
The objective of this fundraising is to strengthen Abionyx’s cash flow as part of its development in sepsis, and to ensure its financial visibility which is now extended until the first quarter of 2025 without a new drawdown of the ORA. .
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
